Amir Zarebkohan | Nanomedicine | Best Researcher Award

Published on by Cell Biologist

Dr. Amir Zarebkohan | Nanomedicine | Best Researcher Award

Tabriz University of Medical Sciences | Iran

Dr. Amir Zarebkohan’s research focuses on the development of advanced nanomedicine strategies for targeted drug delivery and cancer therapy. His work integrates medical nanotechnology and physiology to design innovative nanosystems capable of precise drug transport within biological environments. He specializes in smart targeted delivery platforms, nano–bio interface studies, and nano chemo-immunotherapy approaches aimed at improving therapeutic efficacy while minimizing systemic toxicity. His current projects involve the co-delivery of cyclophosphamide and HLH peptide using D8 and RIVAP-modified chitosan nanoparticles, engineered to respond to the redox conditions of the tumor microenvironment for glioma targeting in rat models. Additionally, he is developing chitosan-based nanoparticles containing dendrimers loaded with cyclophosphamide and sitagliptin, further functionalized with targeting ligands for enhanced delivery efficiency. His research emphasizes translational applications of nanotechnology in oncology and the exploration of biocompatible polymeric carriers for controlled and localized drug release. Through his studies, Dr. Zarebkohan contributes to advancing nano-chemoimmunotherapeutic platforms that bridge the gap between nanoscience and clinical medicine, offering potential breakthroughs in the treatment of complex and resistant cancers.

Profiles:  Google Scholar | Scopus | Orcid

Featured Publications:

Zarebkohan, A., & colleagues. (2024). Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model. Scientific Reports, 14, Article 75042.

Zarebkohan, A., & colleagues. (2024). Discovery of a novel dual targeting peptide for human glioma: From in-silico simulation to acting as targeting ligand. Advanced Pharmaceutical Bulletin, 14, Article 033.

Zarebkohan, A., & colleagues. (2023). Dual targeting salinomycin-loaded smart nano-micelles for enhanced accumulation and therapeutic outcome in breast cancer. International Journal of Pharmaceutics, 123095.

Zarebkohan, A., & colleagues. (2023). CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice. International Journal of Pharmaceutics, 122815.

Zarebkohan, A., & colleagues. (2023). Exosomal transmission of viruses, a two-edged biological sword. Cell Communication and Signalling, 21, Article 37.

Cesare Orlandi | GPCR signaling pathways | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Cesare Orlandi | GPCR signaling pathways | Best Researcher Award

Assoc. Prof. Dr. Cesare Orlandi, University of Rochester, United States

Dr. Cesare Orlandi is an accomplished Associate Professor of Pharmacology and Physiology at the University of Rochester School of Medicine & Dentistry. With a multidisciplinary background in pharmaceutical biotechnology and molecular genetics, Dr. Orlandi has made significant contributions to GPCR (G protein-coupled receptor) biology, orphan receptor deorphanization, and signal transduction. His work bridges basic molecular pharmacology with translational applications in neuroscience and immunology. He has authored numerous high-impact publications in leading journals like Science, Nature Communications, and Journal of Medicinal Chemistry. His collaborative research with global institutions reflects a strong network and broad scientific reach. Recognized for his excellence in science communication, Dr. Orlandi has received multiple “Best Talk” awards at competitive research symposia. His lab continues to innovate at the frontier of receptor biology, influencing therapeutic strategies in neurobiology and inflammation.

Publication Profile: 

Scopus

Orcid

Strengths for the Award:

  1. High-Impact Publications in Prestigious Journals
    Dr. Orlandi has published in top-tier, peer-reviewed journals, including Science, Nature Communications, PNAS, Journal of Physiology, and Molecular Pharmacology. This reflects the scientific rigor, innovation, and broad relevance of his work.

  2. Research Innovation in GPCR Biology
    His research into orphan G protein-coupled receptors (GPCRs) has led to the development of new experimental assays (e.g., GzESTY) and has provided significant insights into immune and neurological signaling mechanisms. These contributions are not only fundamental but also highly translational, aligning with drug discovery and therapeutic interventions.

  3. Strong Interdisciplinary and Collaborative Profile
    Dr. Orlandi’s collaborations with diverse teams across pharmacology, structural biology, and immunology underscore his interdisciplinary approach. His name appears alongside experts from multiple institutions, showing leadership in team science.

  4. Recognition for Scientific Communication
    His awards for Best Talk at Scripps Research Fest (2016, 2018) and selection for a Gordon Research Seminar oral presentation affirm his strength in communicating complex science effectively—an essential trait for broader impact.

  5. Mentorship and Leadership
    As an Associate Professor at the University of Rochester, Dr. Orlandi plays an active role in training the next generation of biomedical researchers, contributing to capacity building in academia.

Areas for Improvement:

  1. Limited Mention of Funding Sources or Grant Leadership
    While his publication record is excellent, there’s no clear listing of major research grants or principal investigator (PI) roles, which are critical markers for research independence and sustainability.

  2. More Visible Clinical or Translational Output
    While his work is biologically impactful, the clinical translation or patenting aspect could be made more visible to demonstrate tangible applications beyond academic impact.

  3. Leadership in International Consortia or Editorial Boards
    Additional involvement in editorial boards, scientific committees, or research policy advisory roles would further bolster his profile as a leader in his field.

Education:

Dr. Orlandi earned his Ph.D. in Molecular Genetics from the University of Brescia, Italy (2005–2009), where he conducted foundational research into genetic signaling mechanisms. Prior to that, he completed a Master of Science in Pharmaceutical Biotechnology at the University of Milan (1998–2004), equipping him with a robust interdisciplinary foundation in drug development, pharmacodynamics, and molecular biology. His academic path reflects a strong European biomedical training system, with emphasis on translational pharmacology and therapeutic innovation. The combination of pharmaceutical science and genetic research uniquely positions Dr. Orlandi to explore receptor biology with a precision medicine lens. His training was further strengthened by postdoctoral research in elite institutions, where he deepened his specialization in orphan GPCR signaling. This education forms the backbone of his research productivity and ability to mentor the next generation of molecular pharmacologists.

Experience:

Dr. Cesare Orlandi currently serves as Associate Professor in the Department of Pharmacology and Physiology at the University of Rochester. He has established himself as a leading voice in the GPCR research community, especially in understanding orphan receptors and their roles in neuronal and immune systems. Prior to this, he held postdoctoral and research positions where he collaborated with global leaders in receptor signaling and neurobiology. His lab combines pharmacological, molecular, and computational approaches to tackle fundamental questions about receptor activity, bias, and downstream signaling. With over a decade of hands-on research experience and extensive publication output, Dr. Orlandi has trained graduate students and postdocs who have progressed into independent academic and industry positions. His multidisciplinary experience spans receptor pharmacology, molecular neuroscience, and drug discovery, making him a cornerstone in collaborative biomedical research projects at the University of Rochester and beyond.

Awards and Honors:

Dr. Orlandi’s scientific excellence has been recognized with several prestigious honors. Notably, he received the Best Talk Award at the Scripps Research Fest in both 2016 and 2018, underscoring his ability to clearly and impactfully communicate complex scientific findings. In 2016, his work was also selected for an oral presentation at the highly competitive Gordon Research Seminar on Phosphorylation and G-Protein Mediated Signaling, affirming the novelty and relevance of his contributions to the receptor signaling field. These awards highlight not only the depth of his scientific insights but also his excellence in mentorship, collaboration, and thought leadership. They place him among a select group of researchers with both technical and communicative brilliance, a critical trait for academic and translational science leadership. These recognitions, combined with high-impact publications, position Dr. Orlandi as a deserving candidate for the Best Researcher Award.

Research Focus:

Dr. Orlandi’s research revolves around orphan G protein-coupled receptors (GPCRs)—a class of proteins that are vital drug targets but remain largely unexplored. His lab develops novel assays (like GzESTY) for GPCR deorphanization, helping decode their physiological roles in the brain and immune system. He also explores signaling bias, investigating how different ligands induce distinct signaling cascades through the same receptor. His recent work uncovered pivotal roles for orphan GPCRs in macrophage immune function and neuronal communication, highlighting their therapeutic potential. Collaborating across pharmacology, neuroscience, and structural biology, he integrates in vitro, in vivo, and computational methods. His lab has also contributed to understanding how GPCRs interact with psychoactive cannabinoids and prostaglandins, which has implications for pain, inflammation, and psychiatric disorders. His research is highly translational, aiming to inform next-generation drug discovery in neuropharmacology and immunomodulation.

Publications Top Notes: 

  1. 🧬 Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons – Journal of Medicinal Chemistry, 2025

  2. 🧪 Pancreatic Exocrine Signaling and Function Require Gαq Activation – The Journal of Physiology, 2025

  3. 🧫 GzESTY: An Optimized Cell-Based Assay for GPCR Deorphanization – Nature Communications, 2025

  4. 🧉 Orphan GPCR GPRC5B Controls Macrophage Function via Prostaglandin E2 Signaling – Nature Communications, 2025

  5. 🧠 Gα Protein Signaling Bias at the 5-HT1A Receptor – Molecular Pharmacology, 2023

  6. 🧠 Spatial Profile of Orphan GPCR GPRC5B Expression in Mouse Brain – Frontiers in Neuroscience, 2022

  7. 🔍 In Vitro Profiling of Orphan GPCR Constitutive Activity – British Journal of Pharmacology, 2021

  8. 🧩 Cell-Adhesion Molecules Regulate Cone Photoreceptor Synaptic Wiring – PNAS, 2020

  9. 🎮 NF1-cAMP Signaling Links Striatal Neurons to Reward and Motor Control – PLOS Biology, 2019

  10. 🚫 Genetic Behavioral Screen Identifies an Orphan Anti-Opioid System – Science, 2019

Conclusion:

Dr. Cesare Orlandi stands out as an exceptional researcher whose work has advanced the frontiers of molecular pharmacology, especially in the complex field of orphan GPCRs. His innovative methodologies, strong publication track record, and interdisciplinary collaborations make a compelling case for recognition through the Best Researcher Award. While there is room to further highlight his grant leadership and translational reach, his scientific output and leadership are already at a level that merits this award.

Abbas Montayeri | Tissue Engineering Regeneration | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Abbas Montayeri | Tissue Engineering Regeneration | Best Researcher Award

Assoc. Prof. Dr. Abbas Montayeri | K N Toosi University of Technology | Iran

Dr. Abbas Montazeri is an Associate Professor in the Faculty of Materials Science and Engineering at K.N. Toosi University of Technology, Tehran, Iran. With over a decade of academic and research experience, Dr. Montazeri specializes in molecular dynamics simulations, computational nanomechanics, and multiscale modeling. He received his Ph.D. in Nanotechnology from Sharif University of Technology, where he also completed his M.Sc. and B.Sc. in Mechanical Engineering. A resident researcher at IPM and director of graduate studies at KNTU, he has led pioneering work in biological nanocomposites, heat transfer at the nanoscale, and drug delivery systems. Dr. Montazeri’s contributions are widely recognized through numerous journal publications, a book chapter, and multiple national awards. His interdisciplinary work bridges fundamental simulation techniques and real-world applications, notably in advanced materials and biomedical engineering. He continues to mentor students and contribute actively to cutting-edge nanotechnology research.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Research Output: Dr. Montazeri has an impressive list of publications in top-tier international journals, demonstrating sustained and high-quality contributions to fields such as molecular dynamics, computational nanomechanics, and biomedical nanocomposites.

  2. Interdisciplinary Expertise: His research covers a diverse array of modern scientific domains, including drug delivery systems, nano-tribology, heat transfer at the nanoscale, and 2D nanostructures, highlighting his adaptability and scientific breadth.

  3. Innovative Methodologies: Use of MD simulations, data-driven modeling, and multiscale approaches showcases cutting-edge methodology with practical implications in biomedical engineering and materials science.

  4. Academic Leadership: Holding key positions such as Director of Graduate Studies and Vice-Chairman for Educational Affairs, he shows commitment not only to research but also to educational excellence and mentorship.

  5. National Recognition: Previous awards (e.g., Distinguished Young Researcher, Exceptional Talent Award) and top national ranks confirm his academic excellence and early recognition in the scientific community.

🛠️ Areas for Improvement:

  1. International Collaboration & Visibility: While publication quality is high, increased collaborations with international institutions could broaden the global impact and citation footprint.

  2. Patent or Industry Linkage: There’s no mention of technology transfer, industrial projects, or patents. Involving industry could enhance real-world application and innovation.

  3. Outreach & Public Engagement: Enhanced visibility through public lectures, conference keynote roles, or scientific community leadership would strengthen the public and academic profile.

🎓 Education:

Dr. Abbas Montazeri holds a distinguished academic record from Sharif University of Technology. He earned his Ph.D. in Nanotechnology/NanoMechanics from the Institute for Nano Science and Technology (2005–2010), where he focused on atomistic simulations and nanostructures. Before that, he completed his M.Sc. in Mechanical Engineering/Applied Design (2002–2004), working on solid mechanics and material behavior. His academic journey began with a B.Sc. in Mechanical Engineering/Solid Mechanics (1998–2002), during which he ranked 22nd nationally among nearly 250,000 candidates. His academic path reflects a steady progression into highly specialized research areas in nanomechanics and computational materials science. Throughout his education, Dr. Montazeri demonstrated academic excellence, receiving exceptional talent awards and high ranks in national entrance exams. His robust educational background laid the foundation for his interdisciplinary research in mechanical engineering, materials science, and biomedical applications.

💼 Professional Experience:

Dr. Montazeri has accumulated extensive professional experience in academia and research. He began his academic career as an Assistant Professor at K.N. Toosi University of Technology in 2012 and was promoted to Associate Professor in 2017. Concurrently, he has served in several administrative roles, including Vice-Chairman of Educational Affairs, Head of Divisions, and currently, Director of Graduate Studies at the Faculty of Materials Science and Engineering. Additionally, he has been a Resident Researcher at the School of Nano Science, IPM, since 2012. These roles reflect his leadership, commitment to education, and continuous contributions to nanotechnology research. His experience spans advanced computational modeling, educational management, and interdisciplinary collaboration. Dr. Montazeri has mentored numerous graduate students and has been instrumental in integrating simulation-based research with practical engineering applications, including drug delivery, tissue engineering, and nano-enabled sensors.

🏆 Awards and Honors:

Dr. Abbas Montazeri has received several prestigious awards that highlight his academic excellence and research contributions. In 2017, he was named a Distinguished Young Researcher at K.N. Toosi University of Technology. His Ph.D. thesis was selected as one of the best at the 7th Iranian Students Nanotechnology Conference in 2010. He was also honored with the Exceptional Talents Award by Sharif University’s Graduate Office in 2006. Early in his academic journey, Dr. Montazeri achieved remarkable ranks in competitive national exams: 20th place in the nationwide graduate entrance exam (2002) and 22nd place in Iran’s university entrance exam (1998) among hundreds of thousands of students. These accolades reflect a consistent pattern of high performance, innovation, and leadership in research and academia. His honors not only recognize past achievements but also underscore his ongoing contributions to materials science, computational mechanics, and nanotechnology.

🔬 Research Focus:

Dr. Montazeri’s research is at the forefront of computational materials science and nanotechnology. His work primarily involves Molecular Dynamics (MD) Simulation, NanoTribology, and Multiscale Modeling Techniques. He applies these methods to study biological nanocomposites for tissue engineering, heat transfer at the nanoscale, drug delivery systems, and 2D nanostructures. A strong focus of his research lies in understanding the mechanical, thermal, and interfacial behavior of materials at the atomic scale. His investigations into nanostructured composites, smart polymers, and surface-functionalized materials have opened new pathways in biomedical applications, especially in therapeutic implants and biosensors. He has also explored sintering processes, failure mechanisms, and data-driven modeling of nanomaterials. Dr. Montazeri’s interdisciplinary approach effectively bridges fundamental theoretical modeling with practical engineering challenges, making significant contributions to both academic literature and industrial innovation in advanced material systems.

📚 Publication Top Notes:

  • 🧪 Theoretical Modeling of CNT-Polymer Interactions – Elsevier Book Chapter (2017)

  • 💊 Molecular dynamics simulation reveals the reliability of Brij-58 nanomicellar drug delivery systems – J. Mol. Liquids, 2022

  • 🧱 Mechanical properties affected by coalescence mechanisms during Al-Cu nanoparticle sintering – Powder Tech, 2022

  • 🧩 Toughening role of surface-treated BN nanosheets in PLA nanocomposites – Eur. Polymer J., 2022

  • 🧪 Failure mechanisms in degraded hybrid composites via acoustic emission analysis – Eng. Failure Analysis, 2022

  • 🧬 Shape memory properties of graphene/polymer nanocomposites – Smart Mater. Struct., 2022

  • 🔬 Optimal sample location in quartz tuning fork biosensors – Biomedical Phys. Eng. Express, 2021

  • 🔥 Temperature-dependent sintering of metal nanoparticles – Powder Tech, 2021

  • 🧷 Adhesion in poly(L-lactic acid)/graphene nanocomposites via end-grafted polymers – Eur. Polymer J., 2021

  • 🌡️ Interfacial thermal conductance in functionalized BN/PLA nanocomposites – Prog. Organic Coatings, 2024

  • 📊 Predicting mechanical properties of defective h-BN nanosheets using data-driven models – Comput. Mater. Sci., 2023

  • ⚙️ Strain-rate plasticity of Ta-Cu nanocomposites for implants – Sci. Reports, 2023

  • 🦷 Mechanical properties of Ta/Cu nanocomposite dental implants – Metals and Mater. Int., 2023

  • 🧬 Neck growth and tensile properties in sintered Al-Cu systems via MD simulation – Adv. Powder Tech, 2023

🧾 Conclusion:

Dr. Abbas Montazeri is a highly qualified and deserving candidate for the Best Researcher Award. His rich research portfolio, technical depth, and consistent academic leadership position him as a leader in computational materials science and nanotechnology. While increasing international partnerships and industry engagement could further amplify his impact, his current accomplishments reflect a strong and balanced research profile that has significantly advanced both fundamental knowledge and applied science in nanomechanics and biomaterials.

HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Prof. Dr. WAN-JEONG JEONG , Department of Nuclear Medicine, Molecular Imaging Therapeutic Medicine Research Center, Jeonbuk Regional Cyclotron Research Center & Biotracer Imaging Lab. Jeonbuk National University Medical School & Hospital, South Korea

Dr. Hwan-Jeong Jeong is a distinguished leader in the field of nuclear medicine, currently serving as Director and Professor at Jeonbuk National University Medical School & Hospital, South Korea. With over two decades of academic and clinical experience, Dr. Jeong has pioneered research in molecular imaging, photobiomodulation, and radiopharmaceutical science. He has made impactful contributions to translational oncology, neuroimaging, and light-based therapeutics. With over 120 peer-reviewed publications, 33 patents, and an H-index of 44, his work bridges the gap between basic science and clinical innovation. Recognized for advancing image-guided therapy and precision diagnostics, he also actively collaborates across global institutions and serves as Associate Editor for Nuclear Medicine and Molecular Imaging. A recipient of multiple national and international recognitions, Dr. Jeong’s efforts continue to shape the future of medical imaging and cancer therapeutics. His commitment to integrating engineering and medicine marks him as a global innovator in nuclear and molecular medicine.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Outstanding Academic and Clinical Background: Dr. Jeong holds an MD, a Master’s in Medical Engineering, and a PhD in Medicine, with postdoctoral training at the prestigious MD Anderson Cancer Center.

  • Leadership in Research: As Director of multiple research centers, he has led over 20 high-impact projects, overseen 5 industry collaborations, and contributed to 120+ SCI-indexed publications.

  • Innovation & Translation: Holder of 33 patents, Dr. Jeong is a pioneer in integrating photobiogoverning, PET/CT imaging, and light-based cancer therapy, bridging lab discoveries and clinical application.

  • Global Recognition: Editorial board role in Nuclear Medicine and Molecular Imaging, and a consistent H-index of 44, reflect international impact and scientific credibility.

  • Cutting-Edge Contributions: Known for novel developments in blue light phototherapy, tumor-targeted radiopharmaceuticals, and noninvasive neuroimaging, significantly advancing cancer and neurological diagnostics.

⚠️ Areas for Improvement:

  • Broader International Collaboration: While highly respected in Korea and internationally, formalizing more international co-research programs or multicenter trials could further expand global reach.

  • Public Engagement & Science Communication: Increasing public visibility through science outreach, open-access publications, or global lectures/webinars can elevate the societal impact of his research.

  • Interdisciplinary Expansion: Potential to integrate AI-based imaging analysis or bioinformatics tools into existing molecular imaging and diagnostics research may boost next-gen innovation.

🎓 Education:

Dr. Hwan-Jeong Jeong began his academic journey at Chonnam National University, where he earned his MD in 1993, followed by a Master’s in Medical Engineering in 2000, and a Ph.D. in Medicine in 2003. He pursued his residency in Nuclear Medicine at Chonnam National University Hospital, gaining a strong clinical foundation. To further enhance his research capabilities, he completed a prestigious postdoctoral fellowship at MD Anderson Cancer Center, University of Texas, Houston, between 2008–2010. His educational path reflects an interdisciplinary approach—blending clinical medicine, biomedical engineering, and advanced imaging sciences. With an emphasis on nuclear medicine and optical diagnostics, Dr. Jeong’s educational background has strategically positioned him at the intersection of clinical practice and high-impact research. His academic evolution reflects a consistent dedication to innovation, translational research, and global collaboration.

🧪 Experience:

Dr. Jeong has served as Director and Professor of Nuclear Medicine at Jeonbuk National University Medical School & Hospital since 2005. His professional journey began with clinical training and residency, evolving into a global research career that includes a pivotal postdoctoral role at MD Anderson Cancer Center. Over the years, he has directed more than 20 research projects, consulted on 5 industry collaborations, and published over 120 scientific papers. Dr. Jeong holds 33 patents, highlighting his innovation in photomedicine and molecular imaging. He leads multiple advanced imaging centers and research labs, including the Molecular Imaging Therapeutic Medicine Research Center and Jeonbuk Regional Cyclotron Research Center. Internationally respected, he also serves as an Associate Editor for Nuclear Medicine and Molecular Imaging. His experience combines clinical expertise, leadership in research infrastructure, and international collaborations that foster innovation and patient-centered imaging solutions.

🔬 Research Focus:

Dr. Jeong’s research lies at the nexus of nuclear medicine, molecular imaging, and photobiomodulation therapy. His groundbreaking work integrates blue light phototherapy, PET/CT molecular imaging, radiopharmaceutical development, and fiber-optic–guided treatment systems for cancers and neurological disorders. He has made significant advances in FDG-PET imaging, amyloid brain scans, and light-triggered tumor therapies, facilitating precision diagnostics and targeted interventions. A key innovator in photobiogoverning—the biological control via light—Dr. Jeong has translated preclinical concepts into clinical applications through rigorous trials and device validation. His projects often explore the interface between biomedical optics and nano-diagnostics, enhancing real-time monitoring and minimally invasive treatments. Through cross-disciplinary collaborations and cutting-edge device design, he has shaped protocols that merge imaging with therapy for high-impact patient outcomes. His research aligns closely with future directions in personalized medicine and oncology imaging.

📚 Publications Top Notes:

  • 📘 From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment

  • 📘 Blue-light activated nanoplatforms for image-guided cancer therapy

  • 📘 Clinical applications of brain amyloid PET imaging in neurodegenerative diseases

  • 📘 Multimodal theranostics using PET/CT and photodynamic therapy in head and neck cancer

  • 📘 Innovative radiotracers for monitoring tumor hypoxia and therapeutic response

  • 📘 Fiber-optic–based interstitial phototherapy in liver malignancies: A pilot clinical study

  • 📘 Nanomedicine-based nuclear imaging in virus-infected tissues

  • 📘 Bioluminescent imaging in evaluating immunotherapy response in solid tumors

  • 📘 Therapeutic implications of photobiogoverning in minimally invasive oncology

  • 📘 Noninvasive tracking of neuroinflammation using fluorinated PET probes

🧾 Conclusion:

Dr. Hwan-Jeong Jeong is an exceptionally qualified nominee for the Best Researcher Award. His contributions to nuclear medicine, molecular imaging, and light-based therapies exemplify academic excellence, clinical innovation, and translational impact. His body of work aligns closely with the award’s values—scientific rigor, real-world application, and forward-thinking medical solutions. With ongoing work in precision diagnostics and phototherapy, he not only meets but exceeds the standards expected of top global researchers in biomedical science. Dr. Jeong’s profile is a model of interdisciplinary leadership, making him a compelling and well-deserved recipient for this prestigious recognition.